Seeking Alpha

On June 29-30, 2013, I interviewed Suleman Verjee, PhD, President and CEO of Versante International. Based in Oakland, CA, Versante is a leader in leveraging biometrics, Statistical Analysis Software (SAS) programming, and data management to provide strategic leadership for drug development plans, protocol development and regulatory submissions. Dr. Verjee, the founder of Versante, is a statistician with more than 30 years of pharmaceutical industry experience focused on assisting companies with new drug application (NDA) and biologics license application (BLA) submissions, streamlining data operations and optimizing clinical development plans. He has been associated with the development, submission and/or approval of several blockbuster drugs and retains a 100% success rate with every drug submission in which he has been actively involved....

Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: